Octreotide Teva 10, 20, 30 10 mg, 20 mg or 30 mg Prolonged release suspension for injection.
PDF Leaflet Revision Date: 15 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of acromegaly and carcinoid tumors.
Dosage (summary)
Start with 20 mg every 4 weeks; may increase to 30 mg or 40 mg based on response.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
- Children
Pregnancy & Breastfeeding
Avoid use during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Beta blockers
- Calcium channel blockers
- Insulin
- Ciclosporin
- Cimetidine
Contraindications
- Hypersensitivity to octreotide or excipients
Common side effects
- Diarrhoea
- Abdominal pain
- Nausea
- Headache
- Cholelithiasis
Counselling Points
- Use contraception if of childbearing potential
- Monitor blood glucose levels
- Report any severe side effects
Serious warnings
- Monitor for tumor expansion
- Thyroid function monitoring
- Gallbladder abnormalities
- Glucose regulation issues
Important Disclaimer
The Octreotide Teva 10, 20, 30 10 mg, 20 mg or 30 mg Prolonged release suspension for injection. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
